[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification

Naoki Takegawa(Kindai University), Kazuhiko Nakagawa(Dana-Farber Cancer Institute)

International Journal of Cancer

May 14, 2019

10.1002/ijc.32408

Cited by 90

Related Papers

DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance

|International Journal of Cancer|2017|193

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

|Clinical Cancer Research|2011|141

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

|British Journal of Cancer|2011|120

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

|British Journal of Cancer|2008|101

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

|Clinical Cancer Research|2021|92